Method for improving implant fixation

• US 5,207,710 A
• Filed: 01/10/1992
• Issued: 05/04/1993
• Est. Priority Date: 09/29/1988
• Status: Expired due to Fees

• Current Assignee: NeuColl, Inc. (Angiotech Pharmaceuticals Incorporated)
• Original Assignee: Collagen Corp. (Abbvie Incorporated)
• Inventors: Chu, George H., Chang, Robert, Armstrong, Rosa
• Primary Examiner(s): Green, Randall L.
• Assistant Examiner(s): NOT, DEFINED
• Application Number:
  US07/819,059
• Time in Patent Office: 480 Days
• Field of Search: 623/16, 623/23
• US Class Current: 128/898
• CPC Class Codes: A61F 2/28 Bones joints A61F2/30
• CPC Class Codes: A61F 2002/30032 differing in absorbability or resorbability, i.e. in absorption or resorption time
• CPC Class Codes: A61F 2002/30677 Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
• CPC Class Codes: A61F 2250/0031 made from both resorbable and non-resorbable prosthetic parts, e.g. adjacent parts
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: A61L 27/227 Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: Y10S 623/923 Bone

Abstract

Stress-bearing prostheses for replacement or partial replacement of stress-bearing bone are fixed in place by bony ingrowth by providing a stress-bearing member having a porous region in combination with an osteogenic factor extract or a purified osteogenic inductive protein, optionally in combination with a TGF-beta cofactor, in a pharmaceutically acceptable carrier. The carrier is preferably either a collagen composition or a ceramic.

Claims

1. A method for permanently fixing a stress-bearing bone-replacement prosthesis having a stress-bearing member by inducing bony ingrowth into the stress-bearing member, where said prosthesis is implanted in a site in a subject, wherein said method comprises:

administering to the site in the subject a substantially pure osteogenically active protein and an effective amount of a transforming growth factor of the beta type in a pharmaceutically acceptable carrier wherein the osteogenic protein and carrier are present in a weight ratio of about 1;

5,000 to 1;

50,000.

2. The method of claim 1 wherein the osteogenic protein and transforming growth factor of the beta type are present in a weight ratio of about 10:

1 to 1;

10.

3. The method of claim 1 wherein the pharmaceutically acceptable carrier comprises collagen.

4. The method of claim 1 wherein the pharmaceutically acceptable carrier is a ceramic.

5. The method of claim 4 wherein the ceramic is selected from the group consisting of hydroxyapatite, tricalcium phosphate, and a mixture thereof.

6. A method for repairing bone defects comprising:

administering to a site of a bone defect a bone replacement composition comprising a substantially pure osteogenically active protein and an effective amount of transforming growth factor of the beta-type in a pharmaceutically acceptable carrier, and a stress-bearing member wherein the osteogenic protein and carrier are present in a weight ratio of about 1;

5,000 to 1;

50,000.

7. The method of claim 6 wherein the stress-bearing member is comprised of a material selected from the group consisting of titanium, stainless steel, an alloy containing titanium, cobalt, chromium, and molybdenum.

8. The method of claim 6 wherein the osteogenic protein and transforming growth factor of the beta type are present in a weight ratio of about 10:

1 to 1;

10.

9. The method of claim 6 wherein the pharmaceutically acceptable carrier comprises a ceramic.

10. The method of claim 6 wherein the pharmaceutically acceptable carrier comprises a ceramic.

11. The method of claim 10 wherein the ceramic is selected from the group consisting of hydroxyapatite, tricalcium phosphate, and a mixture thereof.

12. A method for fixing a stress-bearing bone-replacement prothesis to a bone, comprising the steps of:

implanting the stress-bearing bone-replacement prothesis in a patient so as to contact bone of the patient wherein transforming growth factor of the beta type and osteogenic factor extract are in a pharmaceutically acceptable carrier and are homogeneously dispersed into pores of the prothesis; and

allowing the prothesis to remain in contact with the bone until bone growth into the pores occurs fixing the prothesis to the bone wherein the osteogenic factor extract and transforming growth factor of the beta type are present in a weight ratio of 10;

1 to 1;

10.